Business Context and Reporting Period
This Form 8-K is filed by Qualigen Therapeutics, Inc. (not Aixcrypto Holdings, Inc.) on May 19, 2025. The company is incorporated in Delaware and its common stock (Symbol: QLGN) trades on The Nasdaq Stock Market LLC. The filing addresses a critical regulatory event regarding the company's continued listing status.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on regulatory compliance issues rather than financial performance data.
Material Changes and Events
- Nasdaq Deficiency Notice: On May 19, 2025, the company received a deficiency notification from Nasdaq regarding its failure to timely file the Quarterly Report on Form 10-Q for the period ended March 31, 2025.
- Delisting Risk: This failure constitutes an additional basis for delisting under Nasdaq Listing Rule 5250(c)(1). The Nasdaq Hearings Panel will consider this deficiency alongside previous issues regarding the company's continued listing.
- Management Response: The company intends to present a plan to regain compliance at a previously scheduled hearing and is working to file the overdue Form 10-Q as soon as practicable.
Guidance, Outlook, and Risks
Management has issued forward-looking statements regarding its plan to regain compliance and the expected timing of the 2024 Form 10-K filing. However, the company explicitly states there can be no assurance that the Nasdaq Panel will grant a further extension or that the company will ultimately regain compliance. Key risks include the potential inability to meet Nasdaq requirements, delays in filing the 2024 Form 10-K, and the possibility of delisting.
Investor Verification Checklist
- Verify the current status of the overdue Form 10-Q for the period ended March 31, 2025.
- Confirm the date and outcome of the scheduled hearing before the Nasdaq Hearings Panel.
- Review the company's most recent annual report (Form 10-K) for detailed "Risk Factors" related to delisting and financial instability.
- Monitor for any press releases or updates regarding the acceptance of the company's compliance plan by Nasdaq.